Foley Advises Arcturus Therapeutics on Exclusive ARCT-154 License Agreement with Meiji Seika Pharma
Foley & Lardner LLP advised Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) on an exclusive license agreement with Meiji Seika Pharma Co., Ltd. relating to the application of Arcturus’ ARCT-154 technology for an undisclosed therapeutic area.
The license agreement was announced as part of an expanded collaboration between Arcturus and Meiji Seika Pharma that also includes a $50 million equity investment by Meiji in Arcturus and a memorandum of understanding establishing the principal terms for a potential collaboration and license agreement for a pandemic preparedness and response program in Japan.
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on liver and respiratory therapeutics. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA COVID vaccine in the world to be approved. Arcturus’ strategic collaborations include Thermo Fisher Scientific for ARCT-032 manufacturing and development, BARDA for pandemic influenza initiatives, and ARCALIS, a Japanese joint venture focused on manufacturing mRNA vaccines and therapeutics. Arcturus’ pipeline includes programs in cystic fibrosis, ornithine transcarbamylase deficiency, phenylketonuria, and Gout. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Foley partner Jane Adams represented Arcturus on the license agreement